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Cholesterol: A Continuing
Controversy
This month in the Hong Kong Practitioner, Drs. Chen
and Lo pose the question "The Cholesterol Controversy, Is
there one?" Their article leaves little doubt that if there
is a controversy, they do not think it is justified. They
support the view that hypercholesterolaemia is a major risk
factor for ischaemic heart disease, that treatment of
hyperlipidaemia produces a regression in atherosclerotic
lesions with an associated reduction in deaths from
myocardial infarction, and that as a result patients with
high blood levels of cholesterol should be identified and
treated.
Their position is shared by a large number of people,
both physicians and patients. Public concern in the USA,
for example, has been reinforced by professional activity, and
it is estimated1 that by 1988 at least 1,000,000 patients were
being treated with cholesterol lowering drugs, and the figure
is undoubtedly much higher now.
Is such concern, and such a high level of intervention,
really justified? I don't believe that it is, and I think there
are problems with the evidence regarding the management
of hypercholesterolaemia that cannot be overlooked.
In the first place it is much harder than might be
supposed to either mount or interpret studies of the
association between risk factors such as hypercholesterolaemia
and consequent disease. Experimental studies are difficult to
apply, and case-control or cohort studies are usually the best
that can be managed.
Case-control studies take patients with established disease
and retrospectively compare them with a disease-free group
for the frequency of exposure to the risk-factor under
investigation. Cohort studies follow people before disease is
established and compare the different frequencies with which
disease develops in people who are and are not exposed to
the risk factor under investigation.
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The problem is that both these types of
study are open to many different forms of bias,
with the result that it is difficult to interpret
their results . Even if a risk factor is identified,
it can be hard to judge whether it actually
causes the disease under investigation, is a
manifestation of the disease process rather than
an antecedent variable, or merely a marker for
some other unidentified factor. If it is not
actually causal, the risk factor might be
predictive of disease, but intervention to modify
it would not make a difference.
The identification of risk for coronary heart
disease provides a striking example of this
dilemma. In 1981 Hopkins and Williams2
compiled a list if 246 factors associated with
coronary heart disease. The list included cold
weather, certain fingerprint patterns, noise, a
non-supportive boss, being an alcoholic, being a
teetotaller, slow beard growth, and increased
levels of serum desaturatcd lecithin!
In the second place, the results of treating
hypercholesterolemia, even if it is a central cause
of atherosclerosis (an assumption that has
recently come under fire3), are also debatable.
Grumbach4 has reviewed four major clinical
t r ia ls of the drug t r e a t m e n t of
hypercholesterolemia. He concludes that even if
drug treatment in middle aged men really can
prevent death and morbidity, the effect is
"modest". He calculates that primary prevention
with gemfibrozil or cholestyramine requires
treating some 50 men for ten years to prevent
one adverse cardiovascular outcome. He also
notes that while all the studies he reviewed
showed a reduction in cardio-vascular deaths,
none showed any benefit in overall mortality
because the small reductions in deaths from
cardiovascular causes were offset by increases in
deaths from other causes.
The failure of trials of cholesterol drugs to
lower the overall mortality has concerned other
authors. Muldoon and his colleagues5 reviewed
the data from six primary prevention trials of
cholesterol reduction, which had involved a total
of 24,847 male patients over some five years.
While mortality from coronary heart disease was
lower in the treated men, the total mortality was
not reduced. They concluded that " . . . . the
failure of cholesterol lowering to affect overall
survival justifies a more cautious appraisal of the
probable benefits of reducing cholesterol
concentrations in the general population". Of
even more concern, a Finnish study6 of
multifactorial primary prevention found that
while during the trial itself a reduction of 46%
in coronary mortality had been achieved, in the
ten years after the trial cardiac deaths and
overall mortality were significantly increased in
the group that had received the intervention!
Results such as these have caused some
authors to question whether in fact there should
not be a moratorium on the use of cholesterol
lowering drugs. Smith and Pekkanan1, for
example, comment "It is difficult to justify the
general use of cholesterol lowering drugs when
the data from clinical trials fail to show
reductions (and may show increase) in mortality".
Writing in "Circulation", a specialist journal
concerned with disease of the cardiovascular
system, Hulley and his colleagues7 also call for a
change in direction on health policy with regard
to cholesterol. They note three important
conclusions that they have drawn from the data
so far accumulated in this area.
First, they note that there is an association
between low levels of blood cholesterol and 11011-
cardiovascular deaths in men and women, which
means that efforts to lower cholesterol in some
patients may not be wise.
Second, they find that there is no
association between high blood cholesterol and
cardiovascular deaths in women and that as a
result except in cases at exceptionally high risk,
screening and treatment of hypercholesterolaemia
in female patients is not justified.
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Third, because primary prevention trials
have shown an increase in non-cardiovascular
deaths of a similar magnitude to the decrease
in cardiovascular deaths, they conclude that for
primary prevention it seems unwise to treat
high blood cholesterol with drugs.
Is there a cholesterol controversy? Unlike
Drs. Chen and Lo, I believe there is. I
think that despite attempts to produce
consensus, considerable confusion continues
to exist over clinical policies with regard to
the investigation and treatment of
hypercholesterolaemia. I find it hard to
escape the conclusion that the claims of
overall benefit in any but very high risk
groups have been overstated, and that the
risks of intervention have been ignored for too
long. •
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